Bayer says wont tolerate unethical behaviour as France probes Monsanto file
Bayer, which acquired Monsanto in a $63 billion deal last year, faces mounting litigations over its weedkiller Roundup, a systemic, broad-spectrum glyphosate-based herbicide.
FRANKFURT: Bayer said on Saturday it did not accept "unethical behaviour" following a French investigation into a suspected file assembled by the German company's seed making unit Monsanto to influence various personalities in France.
The French prosecutor said on Friday it had opened the probe after a complaint was filed by the daily newspaper Le Monde.
According to the newspaper and other French media, Monsanto built up a file of some 200 names that includes journalists and lawmakers in the hope of influencing their positions on pesticides.
Read Also: Bayer can absorb Roundup costs of 5 billion euros, but not 20 billion – Moody’s
The file, Le Monde reported, dates from 2016 and was leaked by U.S public relations and marketing agency FleishmanHillard.
In an emailed statement, Bayer declined to comment on the investigation, saying it did not know which documents the allegations referred to.
"We stand for openness and fair treatment of all interest groups. We do not accept any unethical behaviour in our company," it said. "That applies obviously for the data privacy regulations in the respective countries as well."
FleishmanHillard said on Friday it would investigate the allegations in Le Monde. The company will "examine the questions raised by certain media outlets about the lists of stakeholders that included publicly available information," it said in a statement.
Read Also: Price pressure in China; Bayer looking into established drugs strategy
Bayer, which acquired Monsanto in a $63 billion deal last year, faces mounting litigations over its weedkiller Roundup, a systemic, broad-spectrum glyphosate-based herbicide.
A U.S. jury in August 2018 found the company liable because Monsanto had not warned users of alleged cancer risks linked to Roundup.
Bayer suffered a similar defeat over the weedkiller last month, while more than 13,000 plaintiffs are claiming damages. The company said last month it intended to defend itself in all lawsuits.
Read Also: Bayer posts 45 percent gain in quarterly earnings
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd